VTVT - vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference | Benzinga
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief Financial Officer, Steven Tuch, its Chief Scientific Officer, Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will be presenting at the Stifel 2023 Healthcare Conference on November 15, 2023, at 9:45 AM EST.
A live webcast of the presentation will be available via the Events section of the Company's investor relations website at https://ir.vtvtherapeutics.com/events.
Investors interested in scheduling a one-on-one meeting with vTv's management should contact their Stifel representative.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type ...